

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
NUTRI.027AAPPLICATION NO.  
10/646,075INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Juturu, et al.FILING DATE  
August 22, 2003

GROUP

1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>[Signature]</i>	1.	3,337,403	08/22/67	Zentner	<i>[Large X]</i>		
	2.	4,297,349	10/27/81	Barcza			
	3.	4,385,052	05/24/83	Zackheim et al			
	4.	4,573,996	03/04/86	Kwiatek et al.			
	5.	4,597,961	07/01/86	Etscom			
	6.	4,839,174	07/13/89	Baker et al.			
	7.	4,908,213	03/13/90	Govil et al.			
	8.	4,943,435	07/24/90	Baker et al.			
	9.	5,250,569	10/05/93	Godfrey			
	10.	5,284,657	02/08/94	Lu et al.			
	11.	5,288,497	02/22/94	Stanley et al.			
	12.	5,622,980	04/22/97	Caldwell et al.			
	13.	5,662,920	09/02/97	Santus			
	14.	5,716,610	02/10/98	Jack et al.			
	15.	5,804,203	09/08/98	Hahn et al.			
	16.	6,123,936	09/26/00	Platz et al.			
	17.	6,132,394	10/17/00	Lankinen			
	18.	6,182,655 B1	02/06/01	Keller et al.			
	19.	6,298,847 B1	10/09/01	Datta et al.			
<i>[Signature]</i>	20.	6,387,394 B1	05/14/02	Baichwal et al.			
	21.	6,418,926 B1	07/16/02	Chawla			

## FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
<i>[Signature]</i>	22.	2,610,522	08/12/98	France	<i>[Large X]</i>			
<i>[Signature]</i>	23.	2,745,498	09/05/97	France				



EXAMINER


DATE CONSIDERED

9/22/2004

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NUTRI.027A	APPLICATION NO. 10/646,075
		APPLICANT Juturu, et al.	
		FILING DATE August 22, 2003	GROUP 11614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	24.	Bassler, T.J. (1978) Hard water, food fibre, and silicon. British Medical Journal 1:919.
	25.	Bonnefont-Rkousselot (2002) Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care 5:561-568.
	26.	Calver, et al. (1992) Effect of local intra-arterial N <sup>G</sup> -monomethyl-L-arginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J. of Hypertension. 10:1025-1031.
	27.	Carlisle, E.M. (1972) Silicon: An essential element for the chick. Science 178:619-621.
	28.	Carlisle, E.M. (1976) In vivo requirement for silicon in articular cartilage and connective tissue formation in the chick. J. Nutr. 106:478-484.
	29.	Carlisle, et al. (1978) A requirement for silicon for bone growth in culture. Fed. Proc. 37:404.
	30.	Carlisle, et al. (1980) A silicon requirement for normal growth of cartilage in culture. Fed. Proc. 39:787.
	31.	Carlisle, E.M. (1980) Biochemical and morphological change associated with long bone abnormalities in silicon deficiency. J. Nutr. 110:1046-1055.
	32.	Chen, P.Y., et al. (1991) L-arginine abrogates salt-sensitive hypertension in dahl/rapp rats. J. Clin. Invest. 88:1559-1567.
	33.	Clarkson, et al. (1996) Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J. Clin. Invest. 97(8):1989-1994.
	34.	Clowes, et al. (1977) Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 265:625-626.
	35.	Cooke, et al. (1994) Is NO an endogenous antiatherogenic molecule. Arteriosclerosis and Thrombosis. 14(5):653-655.
	36.	Creager, et al. (1992) L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. 90:1248-1253.
	37.	Curtis, et al. (1997) Nitric oxide supplementation or synthesis block-which is the better approach to treatment of heart disease?, Trends in Pharmacological Sciences. 18(7):239-244.
	38.	Drexler, et al. (1991) Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338:1548-1550.
	39.	Edelman, et al. (1990) Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc. Natl. Acad. Sci. USA. 87:3773-3777.
	40.	Eisinger et al. (1993) Effects of silicon, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. Magnesium Research. 6(3):247-249.
	41.	Garson, et al. (1971) Organosilicon entities as prophylactic and therapeutic agents. J. of Pharmaceutical Sciences. 60(8):1113-1127.
	42.	Guyton, et al. (1980) Inhibition of rat arterial smooth muscle cell proliferation by heparin. Circ. Res. 46:625-634.
	43.	Hott et al. (1993) Short-term effects of organic silicon on trabecular bone in mature ovariectomized rats. Calcif. Tissue Int. 53:174-179.
	44.	Laurant, et al. (1995) Dietary L-arginine attenuates blood pressure in mineralocorticoid-salt hypertensive rats. Clin. and Exper. Hypertension 17(7):1009-1024.
	45.	Loeper, et al. (1979) The antiatheromatous action of silicon. Atherosclerosis 33:397-408.
	46.	Loeper, et al. (1978) The physiological role of the silicon and its antiatheromatous action, in biochemistry of silicon and related problems. Bendz G. et al. Eds. Plenum Press, NY 281-296.
	47.	Luscher, T.F. (1991) Endothelium-derived nitric oxide: The endogenous nitrovasodilator in the human cardiovascular system. Eur. Heart J., 12(Suppl. E):2-11.
	48.	Maulik, et al. (1995) Nitric oxide signaling in ischemic heart. Cardiovasc. Res. 30(4):593-601.
	49.	McPherson et al. (2002) Superoxide activates constitutive nitric oxide synthase in a brain particulate fraction. Biochemical and Biophysical Research Communications. 296:413-418.
	50.	Moncada, et al. (1993) The L-arginine-nitric oxide pathway. The New. Engl. J. of Med. 329(27):2002-2012.
	51.	Parr, R.M. (1980) Silicon, wine, and the heart. Lancet pg. 1087.

EXAMINER 	DATE CONSIDERED 9/22/2004
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 606; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NUTRI.027A	APPLICATION NO. 10/846,075
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Juturu, et al.	
		FILING DATE August 22, 2003	GROUP 1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
	52. Rubanyi, M.D., Ph.D. (1991) endothelium-derived vasoactive factors in health and disease, in cardiovascular significance of endothelium-derived vasoactive factors. Rubanyi, G.M., ed., Futura Publishing Company, Inc., NY xi-xix.
	53. Schwarz, et al. (1972) Growth-promoting effects of silicon in rats. Nature. 239:333-334.
	54. Schwarz, K., Silicon (1977) Fibre, and atherosclerosis. Lancet. 454-457.
	55. Schwarz, et al. (1977) Inverse relation of silicon in drinking water and atherosclerosis in finland. Lancet 538-539.
	56. Schwarz, K. (1978) Significance and functions of silicon in warm-blooded animals, in biochemistry of silicon and related problems. Bendz, G. et al., Eds., Plenum Press, NY 207-230.
	57. Svehla, G. (1979) Reaction of silicates. Vogels Textbook of Macro and Semimicro Qualitative Inorganic Analysis 5 <sup>th</sup> Edition, Longman, London pgs. 350-353.
	58. Tsao, et al. (1994) Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine. Circulation 89(5):2176-2182.
	59. Wang et al. (1998) Effects of nitric oxide synthase inhibitors on systemic hypotension, cytokines and inducible nitric oxide synthase expression and lung injury following endotoxin administration in rats. J. Biomed. Sci. 6:28-35.

S:\DOCS\MKD\MKD-3908.DOC\111803

EXAMINER	DATE CONSIDERED 9/22/2004
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
NUTRI.027AAPPLICATION NO.  
10/648,075INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

APR 26 2004

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT  
Juturu et al.FILING DATE  
08/22/2003GROUP  
4628 1614

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>RA</i>	6,344,444 B1	02/05/02	McCarty et al.			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER  
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

<i>RA</i>	Courtesy copy of International Search Report dated April 14, 2004 in 1 page. OF PCT/US03/26370

S:\DOCS\WMD\WMD-4233.DOC\042304

EXAMINER

DATE CONSIDERED

9/22/2004

\*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.